Table 5.
Subjects meeting increased sleep propensity criteria for average SOL by M-MSLT (full analysis set)
| Average SOL based on M-MSLT | Placebo (n = 68) | LEM5 (n = 69) | LEM10 (n = 68) | FLZ (n = 68) |
|---|---|---|---|---|
| <8.0 min, n (%) | 3 (4.4) | 11 (15.9) | 20 (29.4) | 36 (52.9) |
| p-Value vs. placebo | 0.0215 | <0.0001 | <0.0001 | |
| p-Value vs. FLZ | <0.0001 | 0.0009 | ||
| >6.0 min shorter than placebo, n (%) | 9 (13.2) | 20 (29.4) | 35 (51.5) | |
| p-Value vs. FLZ | <0.0001 | 0.0041 | ||
| <8.0 min and >6.0 min shorter than placebo, n (%) | 4 (5.9) | 13 (19.1) | 25 (36.8) | |
| p-Value vs. FLZa | <0.0001 | 0.0118 |
a p-Values vs. placebo or vs. FLZ using McNemar’s test.
FLZ, flurazepam 30 mg; LEM5, lemborexant 5 mg; LEM10, lemborexant 10 mg; M-MSLT, Modified Multiple Sleep Latency Test; SOL, sleep onset latency.